Medicenna Announces the Peer-Reviewed Publication of Clinical Data from Phase 2b Trial Evaluating MDNA55 in Recurrent Glioblastoma
07 mai 2021 09h00 HE
|
Medicenna Therapeutics Corp.
-- Data published in Clinical Cancer Research indicate that early determination of PFS with modified RANO criteria may be a strong surrogate for overall survival in recurrent glioblastoma --...
Medicenna Therapeutics Announces the Appointment of Industry Veteran, Kevin Moulder, PhD, as Chief Scientific Officer
21 avr. 2021 09h00 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, April 21, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today...
Medicenna to Present at the Bloom Burton & Co. Healthcare Investor Conference
14 avr. 2021 09h00 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, April 14, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today...
Medicenna Presents Preclinical Data Demonstrating Potent Immune Modulating Effects of an IL-2/IL-13 Dual Specific Cytokine at the 2021 AACR Annual Meeting
12 avr. 2021 07h00 HE
|
Medicenna Therapeutics Corp.
-- The IL-2/IL-13 dual specific cytokine selectively stimulates anti-cancer immune cells and inhibits M2a polarization of pro-tumoral macrophages -- Data demonstrate the potential to overcome...
Medicenna Announces Preclinical Data on MDNA11 with Anti-PD-1 Therapy and Unveils Novel Bifunctional Superkines at the Cytokine-Based Cancer Immunotherapies Summit
25 mars 2021 07h00 HE
|
Medicenna Therapeutics Corp.
-- MDNA11 and anti-PD-1 combination leads to complete responses in a murine solid tumor model -- Preclinical data demonstrates the potential of BiSKITsTM (Bi-functional SuperKine ImmunoTherapies)...
Medicenna Therapeutics Announces Upcoming Presentation at the AACR Annual Meeting 2021
11 mars 2021 07h00 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, March 11, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today...
Medicenna Therapeutics to Present at Upcoming March Investor Conferences
04 mars 2021 07h00 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today...
Medicenna to Present at the Cowen 41st Annual Healthcare Conference
22 févr. 2021 07h00 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...
Medicenna to Present at the 10th Annual SVB Leerink Global Healthcare Conference
17 févr. 2021 07h00 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today...
Medicenna Reports Third Quarter Fiscal 2021 Financial Results and Operational Highlights
12 févr. 2021 07h00 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “Company") (NASDAQ: MDNA, TSX: MDNA), a clinical stage immuno-oncology company, today announced...